Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depression; Bipolar Disorder
Intervention: bupropion SR (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Massachusetts General Hospital Official(s) and/or principal investigator(s): Joseph Biederman, MD, Principal Investigator, Affiliation: Massachusetts General Hospital
Summary
This is an 8-week open label study of bupropion SR in the treatment of youth with bipolar
depression with adequate mood stabilization. All youth will be closely monitored for
treatment emergent manic activation and drug-drug interactions with ongoing antimanic
agents.
The main objective of this study is to assess the safety and effectiveness of bupropion SR
in the treatment of bipolar depression in children and adolescents.
Clinical Details
Official title: Open-Label Study of Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar and Bipolar Spectrum Disorder
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: reduction in depression symptoms assessed byChildren's Depression Rating Scale Hamilton Depression Rating scale (HAM-D)
Detailed description:
While anti-manic agents can effectively control manic symptoms, bipolar patients frequently
continue to struggle with residual depressive symptomatology that can be associated with
severe morbidity and suicidality. Because antidepressants can activate manic symptoms in
bipolar patients with depression, the treatment of bipolar depression poses unique and
challenging therapeutic dilemmas Thus, the identification of appropriate safe and effective
treatment strategies for the management of depression in bipolar youth is particularly
taxing considering that pediatric mania is predominantly mixed with a strong depressive
component. A recent study in our program of bupropion SR in 30 adults with ADHD and Bipolar
disorder, treatment with bupropion SR was extremely well tolerated and was not associated
with activation of manic symptoms. Because bupropion has not been evaluated in the treatment
of bipolar depression in youth, there is a pressing need to evaluate its effectiveness and
safety in the context of a treatment protocol aimed at carefully evaluating this issue.
This is an 8-week open label study of bupropion SR in the treatment of youth with bipolar
depression with adequate mood stabilization. All youth will be closely monitored for
treatment emergent manic activation and drug-drug interactions with ongoing antimanic
agents.
The main objective of this study is to assess the safety and effectiveness of bupropion SR
in the treatment of bipolar depression in children and adolescents.
Eligibility
Minimum age: 6 Years.
Maximum age: 17 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males and females age 6 to 17 with a diagnosis of current depression with bipolar
disorder based on clinical assessment and confirmed by structured diagnostic
interview plus an initial Hamilton rating scale score >17 and a Young Mania Rating
Score of < 15.
- Children will only be allowed to participate in the trial if they have had mood
stabilization on a steady dose of medication for at least 2 months. By mood
stabilization we mean as determined by principle investigator, evaluator clinician,
and as confirmed by KSADS.
- Subject and parent must have a level of understanding sufficient to communicate
intelligently with the investigator and study coordinator, and to cooperate with all
tests and examinations required by the protocol.
- Subjects and their legal representative must be considered reliable.
- Each subject and his/her authorized legal representative must understand the nature
of the study. The subject's authorized legal representative must sign an informed
consent document and the subject must sign an informed assent document.
- Subject must be able to participate in mandatory blood draws.
- Subject must be able to swallow pills.
Exclusion Criteria:
Subjects with chronic medical illness, DSM-IV substance dependence within the past month,
pregnant or nursing female subjects will be excluded from this study.
- Investigator and his/her immediate family; defined as the investigator's spouse,
parent, child, grandparent, or grandchild.
- Serious, unstable illness including hepatic, renal, gastroenterological, respiratory,
cardiovascular, endocrine, neurologic, immunologic, or hematologic disease.
- History of severe allergies or multiple adverse drug reactions.
- Non-febrile seizures without a clear and resolved etiology.
- Leukopenia or history of leukopenia without a clear and resolved etiology.
- Judged clinically to be at serious suicidal risk.
- Acute Psychosis
- Any other concomitant medication with primarily central nervous system activity other
than specified in Concomitant Medication portion of the protocol.
- History of intolerance or non-response to bupropion.
- Treatment with nonreversible monoamine oxidase inhibitor within 2 weeks prior to
initiation of study.
- Current diagnosis of schizophrenia.
- History of head trauma
- CNS tumor
- Diabetic treated with oral hypoglycemics or insulin
- Current or prior diagnosis of bulimia or anorexia
Locations and Contacts
Massachusetts General Hospital, Cambridge, Massachusetts 02138, United States
Additional Information
Starting date: January 2005
Last updated: July 14, 2011
|